What are the key considerations for oral health care providers when treating patients with fibromyalgia. How does fibromyalgia impact oral health and dental treatment. What oral manifestations are common in fibromyalgia patients. How can dental professionals effectively manage fibromyalgia-related oral symptoms.

Understanding Fibromyalgia: A Complex Chronic Pain Syndrome

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread musculoskeletal pain, specific tender points, stiffness, and fatigue. This condition can significantly impact a patient’s quality of life, affecting various regions of the body, including the orofacial area. As oral health care providers, it’s crucial to understand the intricacies of this condition to provide optimal care for patients with fibromyalgia.

Epidemiology of Fibromyalgia

FM affects a significant portion of the population, with prevalence rates ranging from 3% to 6%. The condition shows a clear gender disparity, affecting up to 4% of men and 2.5-10.5% of women. The peak onset of FM typically occurs in middle age, between 45 and 60 years. Interestingly, there’s a familial predisposition to FM, with first-degree relatives being 8.5 times more likely to develop the condition compared to the general population.

Socioeconomic Factors and Fibromyalgia

FM prevalence is higher in lower socioeconomic groups. This correlation may be partly attributed to the increased likelihood of individuals in these groups working in manual occupations, which can lead to more frequent trauma and pain experiences. This socioeconomic aspect is an important consideration for healthcare providers when assessing and treating patients with FM.

The Complex Pathophysiology of Fibromyalgia

The etiology of FM remains elusive, with current understanding pointing towards a multifactorial origin. While genetic factors are suspected to play a role, specific genes associated with FM have not been definitively identified. However, research suggests that genes related to serotonin and dopamine pathways may be involved in the pathogenesis of FM.

Neuroendocrine Dysfunction in Fibromyalgia

Neuroendocrine abnormalities are frequently observed in FM patients. These include hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and sympathoadrenal system, as well as relative hypocortisolism. Both emotional and physical stress can significantly impact the HPA axis, potentially exacerbating FM symptoms.

Neurotransmitter Imbalances in Fibromyalgia

FM patients often exhibit neurotransmitter imbalances that contribute to their symptoms. For instance:

• Substance P levels in the cerebrospinal fluid are typically three times higher in FM patients compared to healthy individuals.
• Increased activation of N-methyl-D-aspartate receptors (NMDAR) is observed in FM patients.
• Serotonin levels in the serum are often reduced and inversely correlated with pain threshold.
• Dopamine levels are typically lower in FM patients, affecting pain perception and natural analgesia.

The interplay between these neurotransmitter imbalances, particularly the combination of low serotonin and high substance P levels, may contribute significantly to the onset and persistence of FM symptoms.

Autonomic Nervous System Dysfunction in Fibromyalgia

Dysfunction of the autonomic nervous system is a common feature in FM patients. This can manifest in various ways, including:

• Syncope, palpitations, and dizziness in response to positional changes
• Reduced heart rate variability due to increased nocturnal sympathetic modulation of the sinus node
• Dysregulation of diurnal cortisol production, leading to cortisol deficiency and maladaptation

These autonomic abnormalities are closely linked to sleep disturbances and fatigue, which are hallmark symptoms of FM.

Inflammatory and Oxidative Stress Factors in Fibromyalgia

Recent research has shed light on the role of inflammatory markers and oxidative stress in FM pathophysiology. Several pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α and interleukin, have been implicated in generating FM symptoms such as sleep disturbances, fatigue, and myalgia.

Oxidative stress is another factor that may contribute to FM pathophysiology. Studies have demonstrated a correlation between lipid peroxidation and pain, depression, and quality of life in FM patients. The severity of pain has been significantly associated with oxidative stress markers.

Oral Manifestations of Fibromyalgia: What Dental Professionals Should Know

FM commonly affects orofacial health, presenting with a variety of oral manifestations. As oral health care providers, it’s crucial to be aware of these potential issues to provide comprehensive care for FM patients.

Temporomandibular Disorders (TMD) in Fibromyalgia Patients

Temporomandibular disorders are frequently observed in FM patients. These may manifest as pain in the temporomandibular joint (TMJ), limited jaw movement, and clicking or popping sounds during jaw movement. The relationship between FM and TMD is complex, with some researchers suggesting that FM may predispose individuals to TMD, while others propose that TMD could be a localized form of FM.

Xerostomia and Its Impact on Oral Health

Xerostomia, or dry mouth, is a common complaint among FM patients. This condition can lead to various oral health issues, including increased risk of dental caries, oral infections, and difficulty in wearing dentures. Dental professionals should be prepared to offer appropriate management strategies for xerostomia in FM patients.

Glossodynia: Burning Mouth Syndrome in Fibromyalgia

Glossodynia, also known as burning mouth syndrome, is another oral manifestation frequently reported by FM patients. This condition is characterized by a burning sensation in the tongue or other oral mucous membranes, often without any visible clinical abnormalities. Understanding and managing this symptom is crucial for improving the quality of life of FM patients.

Dysgeusia: Taste Alterations in Fibromyalgia Patients

Dysgeusia, or altered taste perception, is sometimes reported by FM patients. This can range from a persistent unpleasant taste to a complete loss of taste. Dental professionals should be aware of this potential symptom and its impact on patients’ dietary habits and overall well-being.

Diagnosis and Treatment Considerations for Fibromyalgia in Dental Practice

While the primary diagnosis of FM is typically made by rheumatologists or pain specialists, dental professionals play a crucial role in identifying potential FM symptoms and referring patients for further evaluation.

Diagnostic Criteria for Fibromyalgia

The American College of Rheumatology has established diagnostic criteria for FM, which include:

1. Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 OR WPI 3-6 and SS scale score ≥ 9.
2. Symptoms have been present at a similar level for at least 3 months.
3. The patient does not have another disorder that would otherwise explain the pain.

Dental professionals should be familiar with these criteria and consider FM as a potential diagnosis when patients present with unexplained chronic orofacial pain.

Treatment Approaches for Fibromyalgia-Related Oral Symptoms

Treatment of FM-related oral symptoms often requires a multidisciplinary approach. Some key considerations include:

• Management of TMD through physical therapy, occlusal splints, and pain medications
• Addressing xerostomia with saliva substitutes, increased water intake, and meticulous oral hygiene
• Symptomatic relief for glossodynia through topical treatments or systemic medications
• Dietary counseling and oral hygiene instruction to mitigate the effects of dysgeusia

It’s important to note that treatment should be tailored to each patient’s specific symptoms and needs.

The Role of Oral Health Care Providers in Fibromyalgia Management

Oral health care providers play a crucial role in the comprehensive management of FM patients. Their responsibilities extend beyond treating oral symptoms to include:

• Early identification of potential FM symptoms and appropriate referral
• Providing education on the nature of FM and its impact on oral health
• Offering guidance on oral self-care modifications to accommodate FM symptoms
• Collaborating with other healthcare providers to ensure holistic patient care

By understanding the complexities of FM and its oral manifestations, dental professionals can significantly contribute to improving the quality of life for patients with this challenging condition.

Future Directions in Fibromyalgia Research and Oral Health Care

As our understanding of FM continues to evolve, several areas of research hold promise for improving the care of FM patients in dental settings:

Personalized Treatment Approaches

Given the heterogeneous nature of FM, future research may focus on developing personalized treatment approaches based on individual patient profiles. This could involve genetic testing, biomarker analysis, and detailed symptom assessment to tailor interventions more effectively.

Novel Pain Management Strategies

Research into new pain management strategies specifically targeting FM-related pain mechanisms could lead to more effective treatments for orofacial pain in FM patients. This might include novel pharmacological agents or innovative non-pharmacological interventions.

Improved Diagnostic Tools

The development of more sensitive and specific diagnostic tools for FM could aid in earlier detection and intervention. This could be particularly relevant for dental professionals in identifying potential FM cases among patients presenting with chronic orofacial pain.

Integration of Oral Health in Multidisciplinary FM Care

Future research may focus on better integrating oral health care into multidisciplinary FM management programs. This could lead to more comprehensive care models that address both systemic and oral manifestations of FM more effectively.

As oral health care providers, staying informed about these developments and participating in relevant continuing education can enhance our ability to provide optimal care for FM patients. By maintaining an up-to-date understanding of FM and its oral manifestations, we can continue to play a crucial role in improving the overall health and quality of life for individuals living with this challenging condition.

Fibromyalgia: practical considerations for oral health care providers

J Dent Anesth Pain Med. 2020 Oct; 20(5): 263–269.

Published online 2020 Oct 30. doi: 10.17245/jdapm.2020.20.5.263

Author information Article notes Copyright and License information Disclaimer

Fibromyalgia is a syndrome characterized by chronic pain in the skeletal system accompanied by stiffness, sleep disturbance, fatigue, and psychiatric problems, such as anxiety and depression. Fibromyalgia commonly affects orofacial health, presenting with a variety of oral manifestations, including temporomandibular disorder, xerostomia, glossodynia, and dysgeusia. Therefore, oral healthcare providers need to be aware of this clinical entity to effectively manage oral symptoms and provide proper oral self-care modification and education on the nature of fibromyalgia. This review focuses on the epidemiology, pathophysiology, clinical manifestation, diagnosis, orofacial concerns, and treatment of fibromyalgia.

Keywords: Dysgeusia, Fibromyalgia, Glossodynia, Oral Health, Temporomandibular Joint Disorder, Xerostomia

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread musculoskeletal pain and specific sites of tenderness, stiffness, and fatigue. In particular, specific tender regions are detected without signs of inflammation in patients with FM. This can severely decrease the quality of life and affect any region in a patient, including the orofacial area [1,2]. Oral care practitioners can detect the early symptoms of FM and assist patients in receiving the proper diagnosis and treatment. The epidemiology, pathophysiology, clinical manifestation, diagnosis, orofacial concerns, and treatment of FM are reviewed here.

FM has been diagnosed in 3–6% of the population, imposing substantial medical costs [3]. It occurs in up to 4% of men and 2.5–10.5% of women with a peak onset of disease in middle age (45–60 years). FM has a familial preponderance with variable manifestations [4,5]. It is prevalent in lower socioeconomic groups, which have members more likely to work in manual occupations, leading to an increase in trauma and pain [6,7].

The etiology of FM is unknown. It is associated with a multifactorial etiology. First-degree relatives with FM are 8.5 times more likely to have this disorder than the general population [5]. However, genetic factors associated with FM are unknown. It has been suggested that serotonin- and dopamine-related genes may play a role in the pathogenesis of FM [8].

Many researchers report that patients with FM have neuroendocrine dysfunctions such as hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and sympathoadrenal system, and relative hypocortisolism [9,10]. Emotional and physical stress can affect the HPA axis [9,10].

Patients with FM have a three times higher concentration of substance P in the cerebrospinal fluid than healthy controls [11]. Activation of the N-methyld-aspartate receptor (NMDAR) is increased in FM patients. Substance P modulates the responsiveness of the NMDAR to glutamate, which consequently leads to temporary central sensitization and temporal summation in otherwise healthy individuals [12,13]. It has been demonstrated that serotonin levels in the serum are reduced and inversely correlated with pain threshold in FM patients [14,15]. Combined dysfunctional neurotransmitter systems, such as low serotonin and high substance P levels, can produce more pain than either abnormality on their own and be responsible for the onset of FM [16,17].

Dysfunction of the autonomic nervous system is common in FM patients. Positional changes often result in syncope, palpitations, and dizziness [18,19]. Heart rate variability among FM patients is reduced due to an increased nocturnal exaggerated sympathetic modulation of the sinus node [18,19]. Abnormal functioning of the HPA axis leads to dysregulation of diurnal cortisol production, which can result in cortisol deficiency and maladaptation [14]. This abnormal chronobiology is linked to sleep disturbances and fatigue in FM patients [14,19].

Research has demonstrated that FM patients have a lower level of dopamine, which plays a central role in modulating pain perception and natural analgesia within supraspinal regions and the spine in painful conditions [20,21]. It was found that several serum pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin, are involved in the generation of symptoms in FM, including sleep disturbances, fatigue, and myalgia [8,22,23,24]. It has been suggested that oxidative stress may also play a role in the pathophysiology of FM. Several studies have shown that lipid peroxidation is correlated with pain, depression, and quality of life in FM patients [24,25]. The severity of pain was significantly associated with oxidized low-density lipoprotein [24].

Physical trauma, infection, and psychosocial factors are reported to be associated with the onset of FM [26,27]. Environmental triggers, such as acute illness and psychosocial stress, may alter the pain modulatory response in the brain, leading to enhanced pain perception [27].

FM is a complex systemic disorder characterized by generalized musculoskeletal pain and specific sites of tenderness, sleep disturbance, stiffness and fatigue, and psychological problems [1,2]. The diagnosis of fibromyalgia is based predominantly on the patient’s history and physical examination findings. However, it is difficult because patients with FM may have several comorbid conditions, such as a history of headaches, temporomandibular disorder (TMD), irritable bowel syndrome, interstitial cystitis, myofascial pain syndrome, and restless leg syndrome [1,28]. FM is defined as a chronic musculoskeletal pain syndrome of unknown etiology, characterized by widespread pain for more than 3 months and tenderness in at least 11 out of 18 tender point sites by the American College of Rheumatology () [29].

Table 1

Excluded studies with reasons

Open in a separate window

Scoring
Widespread pain index: Count the number of regions the patient reports pain within the last week
Score will range from 0 to 19.
Symptom severity scale score*: Indicate how severe each of these three symptoms (fatigue, waking unre-freshed, cognitive symptoms) have been over the past week using the following scale:
0 – No problem
1 – Slight or mild problems
2 – Moderate, often present and/or at a moderate level
3 – Severe, continuous, life-disturbing problems
Considering common other symptoms, note whether the patient has:
0 – No symptoms
1 – Few symptoms
2 – A moderate amount of symptoms
3 – Many symptoms

Open in a separate window

^*The symptom severity scale score is the sum of the severity of the three symptoms (fatigue, waking unrefreshed, cognitive symptoms) and the extent of the other symptoms in general. The score ranges between 0 and 12.

Psychiatric conditions, such as depression, panic disorder, anxiety, and post-traumatic stress disorder, are common in FM patients [30]. FM patients are more than three times as likely to have psychiatric disorders than the general population. It was found that the psychiatric disorders associated with FM greatly compromise the quality of life of affected patients [31,32]. Sleep disturbances such as non-restorative sleep, insomnia, and poor quality sleep, are reported to be higher in patients with FM, which is strongly associated with pain and fatigue [1,33].

Many patients with FM have orofacial pain disorders, such as TMD and oral complaints [22,34].

TMD is a term encompassing chronic orofacial pain conditions involving the masticatory muscles, temporomandibular joint, and associated structures. The exact etiology and progression of TMD are poorly understood, while the primary pathology appears to be a degenerative condition, such as osteoarthritis or osteoarthrosis [22,35]. The prevalence of TMD ranges from 42% to 94% in FM patients [35,36]. Therefore, it was suggested that FM may be a predisposing factor for the onset of TMD [37,38]. It has been reported that the masticatory muscles are sensitive and can be tender points in patients with FM [37]. The comorbidity of TMD and FM may lead to or be a consequence of the centrally mediated alteration in pain perception [39,40,41]. Therefore, routine treatments for patients with TMD and FM may not be effective [39]. Occlusal splints were found to be ineffective in relieving myofascial pain in patients with widespread pain [42]. It was reported that full body tactile stimulation using massage was effective to improve the signs and symptoms of TMD in patients who are refractory to conservative TMD treatment [43]. Failure to diagnose underlying FM may not provide appropriate treatment. FM patients with TMD are associated with several comorbidities and psychosocial problems.

FM patients may present with numerous oral complaints, such as xerostomia, glossodynia, and dysgeusia.

Xerostomia, known as dry mouth, is a subjective sensation of dryness in the mouth, which often accompanies salivary gland hypofunction. The incidence of xerostomia with FM varies from 7% to 71% [39,44]. FM patients with various comorbidities are usually managed with xerostomia-inducing medications including antidepressants, sedatives, and muscle relaxants [44,45]. It was demonstrated that about 71% of FM patients have xerostomia, while only 27.5% of FM patients receive xerogenic medications [44]. This suggests a significant prevalence of xerostomia in FM patients independent of the use of xerogenic medications [44]. Xerostomia can increase the rates of caries, periodontal disease, dysphasia, mouth ulcers, and candidiasis. Therefore, it is important to provide appropriate treatment for xerostomia and avoid oral complications [45].

Glossodynia (burning mouth syndrome) is also commonly noted in FM patients. Approximately 33% of patients with FM experience glossodynia [44]. Hormonal disturbance, malnutrition, and depression are also associated with burning mouth syndrome [44,46]. The exact etiology and pathogenesis of burning mouth syndrome remains unclear. Neurological mechanisms, including peripheral neurogenic damage and central hyperexcitability, may induce hyperalgesia and allodynia in FM patients with glossodynia [39,44]. Antidepressants, such as amitriptyline, are reported to be effective in treating FM with glossodynia [39,47]. In addition, the use of saliva substitutes and sialagogues and avoiding consumption of alcohol and caffeine are recommended for FM patients with xerostomia [39,47].

Dysgeusia is a taste disorder that causes foul, rancid, metallic, or salty taste perception. Dysgeusia was reported in 34.2% of FM patients [44]. This can represent a symptom of somatization or side effect of xerogenic medications [44,46].

Headache is reported by 35% to 82% of FM patients [48,49]. Migraine or tension-type headache is common in FM patients. It was demonstrated that chronic headache was endorsed by 76% of treatment-seeking FM patients, with 84% reporting substantial or severe impact from their headaches [40,48]. Therefore, it was suggested that assessment of headache should be a part of the routine evaluation of patients with FM [49].

The clinical presentation of FM varies. Patients should be questioned about a detailed history of orofacial complaints, current medications, and commodities. When the diagnosis of FM is suspected, the patients can be referred to a pain physician or rheumatologist for appropriate diagnostic workup and treatment [46].

A multidisciplinary approach is required for the treatment of patients with FM. Education, pharmacological therapy, and nonpharmacological therapy are the mainstay of treating pain and associated conditions in patients with FM (). [1,2]. Strategies to reduce stress during oral care, build a trusting relationship between the patient and the practitioner, and provide effective pain management are required [39]. One of the most important aspects in the treatment of FM is to recognize the nature of this disease. FM is not an acute but chronic condition [39,46,50]. Therefore, the aim of treatment is to manage symptoms of FM, such as pain, sleep disturbance, and depression. A variety of medications are used to treat the symptoms of FM (). Polypharmacy is usually employed. Pharmacological treatment should be guided toward pain as well as comorbidities. Healthcare providers should be familiar with the side effects of drugs and possible adverse drug reactions associated with multiple medications. For instance, combined treatment with antidepressants and anticonvulsants can increase dry mouth, sedation, dizziness, and constipation, compared with that with each treatment alone [50].

Table 2

Treatments for fibromyalgia

Open in a separate window

Open in a separate window

Open in a separate window

Pharmacological treatment alone is often ineffective in treating FM [39]. The combination of education, cognitive behavioral therapy, and exercise regimens with pharmacologic treatment are important for managing FM [50]. These therapies are reported to provide long-term beneficial effects with an improvement in symptoms and overall quality of life [46,49,50]. Psychological interventions, including basic body awareness therapy, cognitive-behavioral therapy, and imagery intervention, are often used for FM [39,50]. Other nonpharmacologic therapies such as heat application and dietary modulation are also effective [50].

Due to pain and comorbidities, it is often difficult for patients with FM to perform effective oral health self-care, which can lead to perioral lesions such as ulceration and aphthous stomatitis [36]. Perioral infection exacerbates stress on the body, which consequently worsens the symptoms of FM. Oral health care providers should frequently monitor oral self-care and help prevent oral diseases and infections [39,46].

FM patients commonly have various psychiatric disorders. It is important to reduce emotional stress and anxiety prior to their oral hygiene treatment. In addition, FM patients often complain of heightened pain sensitivity and fatigue [27]. Poor management of pain and stress can lead to adverse patient outcomes. Therefore, pretreatment with anti-anxiety drugs and topical and local anesthetic agents is beneficial for the management of discomfort during oral healthcare [39,50].

FM affects the overall health of patients, and FM patients commonly present with a variety of oral manifestations, including temporomandibular disorder, xerostomia, glossodynia, and dysgeusia. Therefore, oral healthcare providers need to be aware of this disorder to better manage oral symptoms and provide proper oral self-care modification and education about the nature of FM. Additionally, it should be considered to provide a stress-free treatment environment.

Contributed by

AUTHOR CONTRIBUTIONS:

• Younghoon Jeon: Writing, review, & editing.

^NOTENo conflicts of interest or funding.

1. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311:1547–1555. [PubMed] [Google Scholar]

2. Morin AK. Fibromyalgia: a review of management options. Formulary. 2009;44:362–373. [Google Scholar]

3. Goldenberg DL, Simms RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum. 1990;33:381–387. [PubMed] [Google Scholar]

4. Neumeister MW, Neumeister EL. Fibromyalgia. Clin Plastic Surg. 2020;47:203–213. [PubMed] [Google Scholar]

5. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944–952. [PubMed] [Google Scholar]

6. Bergman S, Herrström P, Högström K, Petersson IF, Svensson B, Jacobsson LT. Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in Swedish population study. J Rheumatol. 2001;28:1369–1377. [PubMed] [Google Scholar]

7. Bergman S. Psychosocial aspects of chronic widespread pain and fibromyalgia. Disabil Rehabil. 2005;27:675–683. [PubMed] [Google Scholar]

8. Buskila D, Neumann L, Press J. Genetic factors in neuromuscular pain. CNS Spectr. 2005;10:281–284. [PubMed] [Google Scholar]

9. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med. 1999;106:534–543. [PubMed] [Google Scholar]

10. Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25:1–35. [PubMed] [Google Scholar]

11. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593–1601. [PubMed] [Google Scholar]

12. Pyke T, Osmotherly PG, Baines S. Measuring glutamate levels in the brains of fibromyalgia patients and a potential role for glutamate in the pathophysiology of fibromyalgia symptoms: a systematic review. Clin J Pain. 2017;33:944–954. [PubMed] [Google Scholar]

13. Dhar M. Pathophysiology and clinical spectrum of fibromyalgia: a brief overview for medical communicators. AMWA Journal. 2011;26:50–54. [Google Scholar]

14. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol. 1997;24:555–559. [PubMed] [Google Scholar]

15. Ernberg M, Voog U, Alstergren P, Lundeberg T, Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain. 2000;14:37–46. [PubMed] [Google Scholar]

16. Cordero MD, Alcocer-Gómez E, Cano-García FJ, de Miguel M, Sánchez-Alcázar JA, Moreno Fernández AMM. Low levels of serotonin in serum correlates with severity of fibromyalgia. Med Clin (Barc) 2010;135:644–646. [PubMed] [Google Scholar]

17. Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2012;2012:741746. [PMC free article] [PubMed] [Google Scholar]

18. Staud R. Autonomic dysfunction in fibromyalgia syndrome: postural orthostatic tachycardia. Curr Rheumatol Rep. 2008;10:463–466. [PubMed] [Google Scholar]

19. Martínez-Lavín M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum. 1998;41:1966–1971. [PubMed] [Google Scholar]

20. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25:3576–3582. [PubMed] [Google Scholar]

21. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother. 2008;8:781–797. [PubMed] [Google Scholar]

22. Kutu FC, Özdolap Ş, Sarikaya S. Pro-inflammatory cytokines and oxidized low-density-lipoprotein in patients with fibromyalgia. Arch Rheumatol. 2018;34:123–129. [PMC free article] [PubMed] [Google Scholar]

23. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia–new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol. 2006;19:5–10. [PubMed] [Google Scholar]

24. Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – a controlled cross-sectional study. Cytokine. 2016;84:25–28. [PubMed] [Google Scholar]

25. La Rubia M, Rus A, Molina F, Del Moral ML. Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status? Clin Exp Rheumatol. 2013;31:121–127. [PubMed] [Google Scholar]

26. Jiao J, Vincent A, Cha SS, Luedtke CA, Kim CH, Oh TH. Physical trauma and infection as precipitating factors in patients with fibromyalgia. Am J Phys Med Rehabil. 2015;94:1075–1082. [PubMed] [Google Scholar]

27. Adams LM, Turk DC. Psychosocial factors and central sensitivity syndromes. Curr Rheumatol Rev. 2015;11:96–108. [PMC free article] [PubMed] [Google Scholar]

28. Hedenberg-Magnusson B, Ernberg M, Kopp S. Symptoms and signs of temporomandibular disorders in patients with fibromyalgia and local myalgia of the temporomandibular system. A comparative study. Acta Odontol Scand. 1997;55:344–349. [PubMed] [Google Scholar]

29. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The american college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–610. [PubMed] [Google Scholar]

30. Buskila D, Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain Headache Rep. 2007;11:333–338. [PubMed] [Google Scholar]

31. Burke NN, Finn DP, Mcguire BE, Roche M. Psychological stress in early life as a predisposing factor for the development of chronic pain: clinical and preclinical evidence and neurobiological mechanisms. J Neurosci Res. 2017;95:1257–1270. [PubMed] [Google Scholar]

32. Carta MG, Moro MF, Pinna FL, Testa G, Cacace E, Ruggiero V, et al. The impact of fibromyalgia syndrome and the role of comorbidity with mood and post-traumatic stress disorder in worsening the quality of life. Int J Soc Psychiatry. 2018;64:647–655. [PubMed] [Google Scholar]

33. Munguía-Izquierdo D, Legaz-Arrese A. Determinants of sleep quality in middle-aged women with fibromyalgia syndrome. J Sleep Res. 2012;21:73–79. [PubMed] [Google Scholar]

34. Pimentel MJ, Gui MS, de Aquino LM, Rizzatti-Barbosa CM. Features of temporomandibular disorders in fibromyalgia syndrome. Cranio. 2013;31:40–45. [PubMed] [Google Scholar]

35. Hedenberg-Magnusson B, Ernberg M, Kopp S. Presence of orofacial pain and temporomandibular disorder in fibromyalgia. A study by questionnaire. Swed Dent J. 1999;23:185–192. [PubMed] [Google Scholar]

36. Korszun A, Papadopoulos E, Demitrack M, Engleberg C, Crofford L. The relationship between temporomandibular disorders and stress-associated syndromes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1988;86:416–420. [PubMed] [Google Scholar]

37. Leblebici B, Pektaş ZO, Ortancil O, Hürcan EC, Bagis S, Akman MN. Coexistence of fibromyalgia, temporomandibular disorder, and masticatory myofascial pain syndromes. Rheumatol Int. 2007;27:541–544. [PubMed] [Google Scholar]

38. Velly AM, Look JO, Schiffman E, Lenton PA, Kang W, Messner RP, et al. The effect of fibromyalgia and widespread pain on the clinically significant temporomandibular muscle and joint pain disorders–a prospective 18-month cohort study. J Pain. 2010;11:1155–1164. [PMC free article] [PubMed] [Google Scholar]

39. Walters A, Tolle SL, McCombs GM. Fibromyalgia syndrome: considerations for dental hygienists. J Dent Hyg. 2015;89:76–85. [PubMed] [Google Scholar]

40. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol. 2003;17:563–574. [PubMed] [Google Scholar]

41. Nguyen TT, Vanichanon P, Bhalang K, Vongthongsri S. Pain duration and intensity are related to coexisting pain and comorbidities present in temporomandibular disorder pain patients. J Oral Facial Pain Headache. 2019;33:205–212. [PubMed] [Google Scholar]

42. Raphael KG, Marbach JJ. Widespread pain and the effectiveness of oral splints in myofascial face pain. J Am Dent Assoc. 2001;132:305–316. [PubMed] [Google Scholar]

43. Adiels AM, Helkimo M, Magnusson T. Tactile stimulation as a complementary treatment of temporomandibular disorders in patients with fibromyalgia syndrome. A pilot study. Swed Dent J. 2005;29:17–25. [PubMed] [Google Scholar]

44. Rhodus NL, Fricton J, Carlson P, Messner R. Oral symptoms associated with fibromyalgia syndrome. J Rheumatol. 2003;30:1841–1845. [PubMed] [Google Scholar]

45. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc. 2003;134:61–69. [PubMed] [Google Scholar]

46. Balasubramaniam R, Laudenbach JM, Stoopler ET. Fibromyalgia: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:589–602. [PubMed] [Google Scholar]

47. Peterson EL. Fibromyalgia: management of a misunderstood disorder. J Am Acad Nurse Pract. 2007;19:341–348. [PubMed] [Google Scholar]

48. Okifuji A, Turk DC, Marcus DA. Comparison of generalized and localized hyperalgesia in patients with recurrent headache and fibromyalgia. Psychosom Med. 1999;61:771–780. [PubMed] [Google Scholar]

49. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome. Clin Rheumatol. 2005;24:595–601. [PubMed] [Google Scholar]

50. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318–328. [PubMed] [Google Scholar]

Oral Health and Fibromyalgia Syndrome: A Systemic Review

1. Sumpton J.E., Moulin D.E. Fibromyalgia. Handb. Clin. Neurol. 2014;119:513–527. doi: 10.1016/b978-0-7020-4086-3.00033-3. [PubMed] [CrossRef] [Google Scholar]

2. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheumatol. 1990;33:160–172. doi: 10.1002/art.1780330203. [PubMed] [CrossRef] [Google Scholar]

3. Fitzcharles M.-A., Perrot S., Häuser W. Comorbid fibromyalgia: A qualitative review of prevalence and importance. Eur. J. Pain. 2018;22:1565–1576. doi: 10.1002/ejp.1252. [PubMed] [CrossRef] [Google Scholar]

4. Hauser W., Ablin J., Fitzcharles M. A., Littlejohn G., Luciano J.V., Usui C., Walitt B. Fibromyalgia. Nat. Rev. Dis. Primers. 2015;1:15022. doi: 10.1038/nrdp.2015.22. [PubMed] [CrossRef] [Google Scholar]

5. Quintner J.L., Cohen M.L. Fibromyalgia falls foul of a fallacy. Lancet. 1999;353:1092–1094. doi: 10.1016/S0140-6736(98)06468-X. [PubMed] [CrossRef] [Google Scholar]

6. Henriksson K.G., Bengtsson A., Larsson J., Lindstrom F., Thornell L.E. Muscle biopsy findings of possible diagnostic importance in primary fibromyalgia (fibrositis, myofascial syndrome) Lancet. 1982;2:1395. doi: 10.1016/S0140-6736(82)91287-9. [PubMed] [CrossRef] [Google Scholar]

7. Cohen M.L., Quintner J.L. Fibromyalgia syndrome, a problem of tautology. Lancet. 1993;342:906–909. doi: 10.1016/0140-6736(93)91950-Q. [PubMed] [CrossRef] [Google Scholar]

8. Szychlinska M.A., Yamakado K., Castorina A., Ljubisavljevic M. The “Journal of Functional Morphology and Kinesiology” Journal Club Series: Highlights on Recent Papers in Musculoskeletal Disorders. J. Funct. Morphol. Kinesiol. 2017;2:10. doi: 10.3390/jfmk2020010. [CrossRef] [Google Scholar]

9. Arnold L.M., Bennett R.M., Crofford L.J., Dean L.E., Clauw D.J., Goldenberg D.L., Fitzcharles M.A., Paiva E.S., Staud R., Sarzi-Puttini P., et al. AAPT Diagnostic Criteria for Fibromyalgia. J. Pain. 2019;20:611–628. doi: 10.1016/j.jpain.2018.10.008. [PubMed] [CrossRef] [Google Scholar]

10. Staud R. Biology and therapy of fibromyalgia: Pain in fibromyalgia syndrome. Arthritis Res. Ther. 2006;8:208. doi: 10.1186/ar1950. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Yunus M.B. Central sensitivity syndromes: A new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin. Arthritis Rheumatol. 2008;37:339–352. doi: 10.1016/j.semarthrit.2007.09.003. [PubMed] [CrossRef] [Google Scholar]

12. Whiting P., Savovic J., Higgins J.P.T., Caldwell D.M., Reeves B.C., Shea B., Davies P., Kleijnen J., Churchill R. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Recenti Prog. Med. 2018;109:421–431. doi: 10.1016/j.jclinepi.2015.06.005. [PubMed] [CrossRef] [Google Scholar]

13. Savovic J., Turner R.M., Mawdsley D., Jones H.E., Beynon R., Higgins J.P.T., Sterne J.A.C. Association Between Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study. Am. J. Epidemiol. 2018;187:1113–1122. doi: 10.1093/aje/kwx344. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Mansournia M.A., Higgins J.P., Sterne J.A., Hernan M.A. Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. Epidemiology. 2017;28:54–59. doi: 10.1097/EDE.0000000000000564. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Velly A.M., Look J.O., Schiffman E., Lenton P.A., Kang W., Messner R.P., Holcroft C.A., Fricton J.R. The effect of fibromyalgia and widespread pain on the clinically significant temporomandibular muscle and joint pain disorders–a prospective 18-month cohort study. J. Pain. 2010;11:1155–1164. doi: 10.1016/j.jpain.2010.02.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Hoffmann R.G., Kotchen J.M., Kotchen T.A., Cowley T., Dasgupta M., Cowley A.W., Jr. Temporomandibular disorders and associated clinical comorbidities. Clin. J. Pain. 2011;27:268–274. doi: 10.1097/AJP.0b013e31820215f5. [PubMed] [CrossRef] [Google Scholar]

18. Karibe H., Goddard G., McNeill C., Shih S.T. Comparison of patients with orofacial pain of different diagnostic categories. Cranio. 2011;29:138–143. doi: 10.1179/crn.2011.022. [PubMed] [CrossRef] [Google Scholar]

19. Kindler L. L., Bennett R.M., Jones K.D. Central sensitivity syndromes: Mounting pathophysiologic evidence to link fibromyalgia with other common chronic pain disorders. Pain Manag. Nurs. 2011;12:15–24. doi: 10.1016/j.pmn.2009.10.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Alonso-Blanco C., Fernandez-de-Las-Penas C., de-la-Llave-Rincon A.I., Zarco-Moreno P., Galan-Del-Rio F., Svensson P. Characteristics of referred muscle pain to the head from active trigger points in women with myofascial temporomandibular pain and fibromyalgia syndrome. J. Headache Pain. 2012;13:625–637. doi: 10.1007/s10194-012-0477-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Suma S., Veerendra Kumar B. Temporomandibular disorders and functional somatic syndromes: Deliberations for the dentist. Indian J. Dent. Res. 2012;23:529–536. doi: 10.4103/0970-9290.104965. [PubMed] [CrossRef] [Google Scholar]

22. De Rossi S.S., Stern I., Sollecito T.P. Disorders of the masticatory muscles. Dent. Clin. N. Am. 2013;57:449–464. doi: 10.1016/j.cden.2013.04.007. [PubMed] [CrossRef] [Google Scholar]

23. De Siqueira S.R., Teixeira M.J., de Siqueira J.T. Orofacial pain and sensory characteristics of chronic patients compared with controls. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013;115:e37–e45. doi: 10.1016/j.oooo.2013.02.014. [PubMed] [CrossRef] [Google Scholar]

24. Cassisi G., Sarzi-Puttini P., Casale R., Cazzola M., Boccassini L., Atzeni F., Stisi S. Pain in fibromyalgia and related conditions. Reumatismo. 2014;66:72–86. doi: 10.4081/reumatismo.2014.767. [PubMed] [CrossRef] [Google Scholar]

25. Jin H., Patil P.M., Sharma A. Topical review: The enigma of fibromyalgia. J. Oral Facial Pain Headache. 2014;28:107–118. doi: 10.11607/ofph.1220. [PubMed] [CrossRef] [Google Scholar]

26. Dahan H., Shir Y., Velly A., Allison P. Specific and number of comorbidities are associated with increased levels of temporomandibular pain intensity and duration. J. Headache Pain. 2015;16:528. doi: 10.1186/s10194-015-0528-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Eisenlohr-Moul T.A., Crofford L.J., Howard T.W., Yepes J.F., Carlson C.R., de Leeuw R. Parasympathetic reactivity in fibromyalgia and temporomandibular disorder: Associations with sleep problems, symptom severity, and functional impairment. J. Pain. 2015;16:247–257. doi: 10.1016/j.jpain.2014.12.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Furquim B.D., Flamengui L.M., Conti P.C. TMD and chronic pain: A current view. Dent. Press J. Orthod. 2015;20:127–133. doi: 10.1590/2176-9451.20.1.127-133.sar. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Gui M.S., Pimentel M.J., Rizzatti-Barbosa C.M. Temporomandibular disorders in fibromyalgia syndrome: A short-communication. Rev. Bras. Reumatol. 2015;55:189–194. doi: 10.1016/j.rbr.2014.07.004. [PubMed] [CrossRef] [Google Scholar]

30. Cummiford C.M., Nascimento T.D., Foerster B.R., Clauw D. J., Zubieta J.K., Harris R.E., DaSilva A.F. Changes in resting state functional connectivity after repetitive transcranial direct current stimulation applied to motor cortex in fibromyalgia patients. Arthritis Res. 2016;18:40. doi: 10.1186/s13075-016-0934-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Fujarra F.J., Kaziyama H.H., Siqueira S.R., Yeng L.T., Camparis C.M., Teixeira M.J., Siqueira J.T. Temporomandibular disorders in fibromyalgia patients: Are there different pain onset? Arq NeuroPsiquiatr. 2016;74:195–200. doi: 10.1590/0004-282X20160017. [PubMed] [CrossRef] [Google Scholar]

32. Robinson L.J., Durham J., Newton J.L. A systematic review of the comorbidity between Temporomandibular Disorders and Chronic Fatigue Syndrome. J. Oral Rehabil. 2016;43:306–316. doi: 10.1111/joor.12367. [PubMed] [CrossRef] [Google Scholar]

33. Losert-Bruggner B., Hulse M., Hulse R. Fibromyalgia in patients with chronic CCD and CMD—A retrospective study of 555 patients. Cranio. 2018;36:318–326. doi: 10.1080/08869634.2017.1334376. [PubMed] [CrossRef] [Google Scholar]

34. Isaia B., Ravarotto M., Finotti P., Nogara M., Piran G., Gamberini J., Biz C., Masiero S., Frizziero A. Analysis of Dental Malocclusion and Neuromotor Control in Young Healthy Subjects through New Evaluation Tools. J. Funct. Morphol. Kinesiol. 2019;4:5. doi: 10.3390/jfmk4010005. [CrossRef] [Google Scholar]

35. Bruno A., Mico U., Lorusso S., Cogliandro N., Pandolfo G., Caminiti M., Zoccali R.A., Muscatello M.R. Agomelatine in the treatment of fibromyalgia: A 12-week, open-label, uncontrolled preliminary study. J. Clin. Psychopharmacol. 2013;33:507–511. doi: 10.1097/JCP.0b013e31829057ae. [PubMed] [CrossRef] [Google Scholar]

36. Fiorillo L., Cervino G., Herford A.S., Lauritano F., D’Amico C., Lo Giudice R., Laino L., Troiano G., Crimi S., Cicciu M. Interferon Crevicular Fluid Profile and Correlation with Periodontal Disease and Wound Healing: A Systemic Review of Recent Data. Int. J. Mol. Sci. 2018;19:1908. doi: 10.3390/ijms19071908. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Isola G., Ramaglia L., Cordasco G., Lucchese A., Fiorillo L., Matarese G. The effect of a functional appliance in the management of temporomandibular joint disorders in patients with juvenile idiopathic arthritis. Minerva Stomatol. 2017;66:1–8. doi: 10.23736/S0926-4970.16.03995-3. [PubMed] [CrossRef] [Google Scholar]

38. Lombardi T., Bernardello F., Berton F., Porrelli D., Rapani A., Camurri Piloni A., Fiorillo L., Di Lenarda R., Stacchi C. Efficacy of Alveolar Ridge Preservation after Maxillary Molar Extraction in Reducing Crestal Bone Resorption and Sinus Pneumatization: A Multicenter Prospective Case-Control Study. Biomed. Res. Int. 2018;2018:9352130. doi: 10.1155/2018/9352130. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Fiorillo L., De Stefano R., Cervino G., Crimi S., Bianchi A., Campagna P., Herford A.S., Laino L., Cicciù M. Oral and Psychological Alterations in Haemophiliac Patients. Biomedicines. 2019;7:33. doi: 10.3390/biomedicines7020033. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Sambataro S., Cervino G., Fiorillo L., Cicciu M. Upper First Premolar Positioning Evaluation for the Stability of the Dental Occlusion: Anatomical Considerations. J. Craniofac. Surg. 2018;29:1366–1369. doi: 10.1097/SCS.0000000000004459. [PubMed] [CrossRef] [Google Scholar]

41. Wroe A.L., Bowers H.M. Beliefs about sharing illness experiences: Development of a scale and relationship with symptoms of fibromyalgia. Br. J. Health Psychol. 2019 doi: 10.1111/bjhp.12376. [PubMed] [CrossRef] [Google Scholar]

42. Tesio V., Ghiggia A., Di Tella M., Castelli L. Utility of the Diagnostic Criteria for Psychosomatic Research in assessing psychological disorders in fibromyalgia patients. J. Affect. Disord. 2019;256:219–220. doi: 10.1016/j.jad.2019.06.013. [PubMed] [CrossRef] [Google Scholar]

43. Onder H., Hamamci M., Alpua M., Ulusoy E.K. Comorbid fibromyalgia in migraine patients: Clinical significance and impact on daily life. Neurol. Res. 2019:1–7. doi: 10.1080/01616412.2019.1630164. [PubMed] [CrossRef] [Google Scholar]

44. Minerbi A., Gonzalez E., Brereton N.J.B., Anjarkouchian A., Dewar K., Fitzcharles M.A., Chevalier S., Shir Y. Altered microbiome composition in individuals with fibromyalgia. Pain. 2019 doi: 10.1097/j.pain.0000000000001640. [PubMed] [CrossRef] [Google Scholar]

45. Jacobs H., Bockaert M., Bonte J., D’Haese M., Degrande J., Descamps L., Detaeye U., Goethals W., Janssens J., Matthys K., et al. The Impact of a Group-Based Multidisciplinary Rehabilitation Program on the Quality of Life in Patients With Fibromyalgia: Results From the QUALIFIBRO Study. J. Clin. Rheumatol. 2019 doi: 10.1097/RHU.0000000000001120. [PubMed] [CrossRef] [Google Scholar]

46. Stacchi C., Lombardi T., Cusimano P., Berton F., Lauritano F., Cervino G., Di Lenarda R., Cicciù M. Bone Scrapers Versus Piezoelectric Surgery in the Lateral Antrostomy for Sinus Floor Elevation. J. Craniofac. Surg. 2017;28:1191–1196. doi: 10.1097/SCS.0000000000003636. [PubMed] [CrossRef] [Google Scholar]

47. Cicciù M., Herford A.S., Cervino G., Troiano G., Lauritano F., Laino L. Tissue fluorescence imaging (VELscope) for quick non-invasive diagnosis in oral pathology. J. Craniofac. Surg. 2017;28:e112–e115. doi: 10.1097/SCS.0000000000003210. [PubMed] [CrossRef] [Google Scholar]

48. Isola G., Cicciu M., Fiorillo L., Matarese G. Association Between Odontoma and Impacted Teeth. J. Craniofac. Surg. 2017;28:755–758. doi: 10.1097/SCS.0000000000003433. [PubMed] [CrossRef] [Google Scholar]

49. Lo Giudice G., Cutroneo G., Centofanti A., Artemisia A., Bramanti E., Militi A., Rizzo G., Favaloro A., Irrera A., Lo Giudice R., et al. Dentin morphology of root canal surface: A quantitative evaluation based on a scanning electronic microscopy study. BioMed Res. Int. 2015;2015 doi: 10.1155/2015/164065. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Herford A.S., Lu M., Akin L., Cicciù M. Evaluation of a porcine matrix with and without platelet-derived growth factor for bone graft coverage in pigs. Int. J. Oral Maxillofac. Implants. 2012;27:1351–1358. [PubMed] [Google Scholar]

51. Maiorana C., Beretta M., Grossi G.B., Santoro F., Herford A.S., Nagursky H., Cicciù M. Histomorphometric evaluation of anorganic bovine bone coverage to reduce autogenous grafts resorption: Preliminary results. Open Dent. J. 2011;5:71–78. doi: 10.2174/1874210601105010071. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Cicciù M., Herford A.S., Stoffella E., Cervino G., Cicciù D. Protein-signaled guided bone regeneration using titanium mesh and Rh-BMP2 in oral surgery: A case report involving left mandibular reconstruction after tumor resection. Open Dent. J. 2012;6:51–55. doi: 10.2174/1874210601206010051. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Giudice G., Cicciù M., Cervino G., Lizio A., Visco A. Flowable resin and marginal gap on tooth third medial cavity involving enamel and radicular cementum: A SEM evaluation of two restoration techniques. Indian J. Dent. Res. 2012;23:763–769. doi: 10.4103/0970-9290.111256. [PubMed] [CrossRef] [Google Scholar]

54. Cervino G., Fiorillo L., Herford A.S., Romeo U., Bianchi A., Crimi S., D’Amico C., De Stefano R., Troiano G., Santoro R., et al. Molecular Biomarkers Related to Oral Carcinoma: Clinical Trial Outcome Evaluation in a Literature Review. Dis. Markers. 2019;2019:11. doi: 10.1155/2019/8040361. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

55. Cervino G., Fiorillo L., Laino L., Herford A.S., Lauritano F., Giudice G.L., Fama F., Santoro R., Troiano G., Iannello G., et al. Oral Health Impact Profile in Celiac Patients: Analysis of Recent Findings in a Literature Review. Gastroenterol. Res. Pract. 2018;2018:7848735. doi: 10.1155/2018/7848735. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

56. Giudice G., Lipari F., Lizio A., Cervino G., Cicciù M. Tooth fragment reattachment technique on a pluri traumatized tooth. J. Conserv. Dent. 2012;15:80–83. doi: 10.4103/0972-0707. 92613. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Crimi S., Fiorillo L., Bianchi A., D’Amico C., Amoroso G., Gorassini F., Mastroieni R., Marino S., Scoglio C., Catalano F., et al. Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data. Viruses. 2019;11:463. doi: 10.3390/v11050463. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Cervino G., Terranova A., Briguglio F., De Stefano R., Famà F., D’Amico C., Amoroso G., Marino S., Gorassini F., Mastroieni R., et al. Diabetes: Oral health related quality of life and oral alterations. Biomed. Res. Int. 2019;2019 doi: 10.1155/2019/5907195. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

59. Troiano G., Laino L., Cicciu M., Cervino G., Fiorillo L., D’Amico C., Zhurakivska K., Lo Muzio L. Comparison of Two Routes of Administration of Dexamethasone to Reduce the Postoperative Sequelae After Third Molar Surgery: A Systematic Review and Meta-Analysis. Open Dent. J. 2018;12:181–188. doi: 10.2174/1874210601812010181. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60. Laino L., Cicciù M., Fiorillo L., Crimi S., Bianchi A., Amoroso G., Monte I.P., Herford A.S., Cervino G. Surgical Risk on Patients with Coagulopathies: Guidelines on Hemophiliac Patients for Oro-Maxillofacial Surgery. Int. J. Environ. Res. Public Health. 2019;16:1386. doi: 10.3390/ijerph26081386. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

61. Fiorillo L. Chlorhexidine Gel Use in the Oral District: A Systematic Review. Gels. 2019;5:31. doi: 10.3390/gels5020031. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Stefano R.D., Bruno A., Muscatello M., Cedro C., Cervino G., Fiorillo L. Fear and anxiety managing methods during dental treatments: Systematic review of recent data. Minerva Stomatol. 2019 doi: 10.23736/S0026-4970.19.04288-2. in press. [PubMed] [CrossRef] [Google Scholar]

63. De Stefano R. Psychological Factors in Dental Patient Care: Odontophobia. Medicina. 2019;55:678. doi: 10.3390/medicina55100678. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

64. Zoccali R., Muscatello M.R., Bruno A., Barilla G., Campolo D., Meduri M., Familiari L., Bonica M., Consolo P., Scaffidi M. Anger and ego-defence mechanisms in non-psychiatric patients with irritable bowel syndrome. Dig. Liver Dis. 2006;38:195–200. doi: 10.1016/j.dld.2005.10.028. [PubMed] [CrossRef] [Google Scholar]

65. Muscatello M.R., Bruno A., Scimeca G., Pandolfo G., Zoccali R.A. Role of negative affects in pathophysiology and clinical expression of irritable bowel syndrome. World J. Gastroenterol. 2014;20:7570–7586. doi: 10.3748/wjg.v20.i24.7570. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

66. Muscatello M.R., Bruno A., Pandolfo G., Mico U., Stilo S., Scaffidi M., Consolo P., Tortora A., Pallio S., Giacobbe G., et al. Depression, anxiety and anger in subtypes of irritable bowel syndrome patients. J. Clin. Psychol. Med. Settings. 2010;17:64–70. doi: 10.1007/s10880-009-9182-7. [PubMed] [CrossRef] [Google Scholar]

67. Muscatello M.R., Bruno A., Mento C., Pandolfo G., Zoccali R.A. Personality traits and emotional patterns in irritable bowel syndrome. World J. Gastroenterol. 2016;22:6402–6415. doi: 10.3748/wjg.v22.i28.6402. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Fibromyalgia

Home / Articles / Fibromyalgia

Fibromyalgia is characterized by chronic generalized skeletal muscle pain caused by a non-inflammatory rheumatic soft tissue lesion. It is a fairly common condition and occurs in 0.5-5% of the population.

Clinical manifestations

Symptoms of fibromyalgia vary. As a rule, patients complain of persistent, diffuse, deep throbbing or cutting pain. Very often fibromyalgia is accompanied by:

• anxiety,
• depressed,
• sleep disorders,
• dizzy,
• difficulty in moving in the morning,
• physical fatigue,
• irritable bowel syndrome.

May be combined with other abnormal conditions:

• TMD;
• Chronic headache;
• Chronic low back pain;
• Intolerance to many chemical compounds.

Common psychiatric disorders associated with fibromyalgia:

• Bipolar disorders;
• Severe depression;
• Eating disorders;
• Abuse of drugs, drugs, alcohol.

Etiology

Genetic and environmental factors play an important role in the development of this disease, as evidenced by the high prevalence of fibromyalgia among blood relatives. This disease belongs to a group of functional somatic symptoms that are similar in clinical manifestations, pathogenesis, epidemiological parameters and treatment strategy.

TMJ and facial pain

Temporomandibular disorders (TMJ) are considered the most common chronic anomaly of the maxillofacial region. You need to know that the term “TMJ” includes several pathological conditions that differ in etiology and pathogenesis. Pain in the facial area is one of the main indicators for the treatment of TMJ. TMJ symptoms are quite common. According to statistics, facial pain occurs in 10-20% of adults, most often at the age of 20-40 years.

TMJ and fibromyalgia

A number of studies have noted the prevalence of the combination of TMJ and fibromyalgia. According to some reports, 53-94% of patients with fibromyalgia have symptoms of TMD. Recent studies suggest that 40% of patients with fibromyalgia have myofascial pain, 30% have disc displacement, and 70% have arthralgia, osteoarthritis, or osteoarthritis.

Despite some common characteristics of fibromyalgia and TMJ, there are some differences between them, in particular in terms of disability and patients’ attitudes towards their condition.

Differential diagnosis of these diseases is carried out using a number of clinical parameters. Studies have shown that fibromyalgia is a significantly more severe disease than TMJ due to multiple painful areas, somatic symptoms, and severe pain intensity.

Thus, despite the possibility of a relationship between TMJ and fibromyalgia, it is still not clear.

Clinical aspects

The effectiveness of TMJ treatment, in particular with occlusal caps, varies depending on the presence or absence of diffuse pain. Therefore, it is advisable to conduct an examination aimed at identifying such pain in patients with facial myofascial pain, since the combination of various disorders can affect the outcome of treatment. In clinical practice, it is necessary to separate the TMJ from TMJ symptoms caused by the spread of fibromyalgia.

With the simultaneous presence of TMJ and fibromyalgia, we can talk about a violation of the central mechanism of pain perception, which explains the insufficient effectiveness of conservative treatment of TMJ.

Methods for the treatment of fibromyalgia

They can be divided into pharmacological and non-pharmacological, which include various psychological effects. Often, the treatment of fibromyalgia requires the help of specialists in various fields of medicine – a physiotherapist, rheumatologist, psychologist, therapist.

Based on the presence of similar symptoms, the differential diagnosis of fibromyalgia and TMJ is significantly difficult. If the results of conservative treatment of TMJ are unsatisfactory, an additional examination is necessary to identify concomitant fibromyalgia. If you suspect fibromyalgia, you should consult a rheumatologist or a general practitioner, as well as a physiotherapist.

Comprehensive hygiene for 2500 rubles! Air Flow 1000p for Braces Patients!

A unique promotion for our regular patients! Complex of hygiene procedures (tartar and plaque removal using Air Flow and ultrasound , scaling, polishing, fluoridation) for regular patients 1 time in 6 months for 3000 rubles!

Air Flow and polishing for only 1500r for patients with braces!

Fibromyalgia – treatment, symptoms, causes, diagnosis

Fibromyalgia is a chronic disease characterized by pain, stiffness and soreness of the muscles, tendons, and joints. Fibromyalgia is also characterized by sleep disturbance, chronic fatigue, depression, anxiety, and bowel dysfunction. Fibromyalgia is sometimes called fibromyalgic syndrome or fibrositis.

Although fibromyalgia is one of the most common diseases affecting muscles, the cause is still unknown. Tissues that are a source of pain are not accompanied by inflammation of this tissue. And therefore, pain, which causes a lot of inconvenience for the patient, does not lead to irreversible changes and destruction of tissues. In addition, there is no damage to internal organs. In this regard, fibromyalgia differs from rheumatic diseases such as rheumatoid arthritis, SLE, or polymyositis. In these diseases, inflammation of the tissues occurs – this is the main cause of pain, stiffness, soreness in the joints, tendons and muscles, and, in addition, damage to both tissues and internal organs occurs.

Causes

The cause of fibromyalgia is unknown. Fibromyalgia patients experience pain in response to stimuli that are not normally perceived as painful. Studies have shown that patients with fibromyalgia have elevated levels of a neurotransmitter (called substance P) and nerve growth factor in their cerebrospinal fluid. In addition, patients with fibromyalgia have reduced levels of serotonin in the brain. A study of pain in fibromyalgia suggested hypersensitivity of the central nervous system. Scientists have also noted disturbances in pain perception in patients with fibromyalgia.

In addition, patients with fibromyalgia reported a decrease in slow eye movements during sleep (which partly explains the feeling of fatigue after sleep or frequent awakenings). The debut of fibromyalgia is often associated with a psychological factor, trauma or infection.

Who is prone to fibromyalgia

Fibromyalgia affects mainly women (up to 80% women suffer) aged 35 to 55 years. Much less frequently, fibromyalgia occurs in men, children, and the elderly. The disease may appear on its own or be associated with other diseases such as SLE or rheumatoid arthritis. The prevalence of this disease varies from country to country. For example, in Sweden and Great Britain 1% and in the USA – 4%.

Symptoms

The universal symptom of fibromyalgia is, of course, pain. As mentioned above, fibromyalgia pain is not caused by tissue inflammation. Instead, patients seem to have hypersensitivity to various sensory stimuli and an unusually low pain threshold. Minor sensory stimulations that do not usually cause great distress to other people can be significant and disruptive in patients with fibromyalgia.

Fibromyalgia pain can be in different parts of the body, and on both sides. Most often, pain occurs in the neck, buttocks, shoulders, in the chest, in the upper body. Sensitive zones are limited areas where there is increased sensitivity.

Fatigue occurs in 90% of patients. Fatigue may be associated with pathological disturbances in sleep phases, which is often observed in these patients. Normally, there are several levels of sleep depth. A person needs to be in a deep stage of sleep for a longer time in order to restore the body’s strength. Fibromyalgia patients lack a deep, restorative level of sleep (called the slow eye movement stage). As a result, patients wake up in the morning feeling tired and with heaviness in the muscles and a feeling of lack of sleep (although the number of hours of sleep was sufficient).

Mental or emotional problems occur in more than half of patients with fibromyalgia. These disorders include poor concentration, impaired fixation memory, irritability, and depressed mood. And due to the fact that the diagnosis of fibromyalgia is difficult to verify, such patients are often diagnosed with depression.

Other symptoms of fibromyalgia may include migraine headaches or tension headaches, various sensations of numbness or tingling in various parts of the body. In addition, there may be discomfort in the abdomen (spasmodic bowel) irritated bladder (frequent sometimes painful urination). But the examination does not show signs of inflammation in the intestines or bladder. Each patient with fibromyalgia is unique in their own way, and symptoms can occur in various combinations.

Diagnosis

There are no tests or x-rays to support the diagnosis of fibromyalgia. Tests and examinations are prescribed to rule out other diseases. The diagnosis of fibromyalgia is based on the history of the disease and physical examination findings. In patients with chronic pain, the diagnosis of fibromyalgia can be made based on the detection of tender points (up to 80% of cases), the presence of tissue inflammation and the exclusion of other diseases. Many diseases have symptoms similar to fibromyalgia. For example, these are diseases such as:0003

• Low thyroid hormone levels (hypothyroidism),
• Vitamin D deficiency
• Increased function of the parathyroid glands (causes an increase in the level of calcium in the blood),
• Muscle diseases accompanied by muscle pain (polymyositis),
• Bone disorders, with bone pain (Paget’s disease),
• Increased blood calcium level (hypercalcemia),
• Infectious diseases (hepatitis, Epstein-Bar virus, AIDS),
• Oncological diseases.

Although blood tests do not confirm fibromyalgia, they are essential for the differential diagnosis. Therefore, it is necessary to do blood tests for thyroid hormones, the level of calcium in the blood (to rule out hypercalcemia, hyperparathyroidism, hypothyroidism). Alkaline phosphatase levels are often elevated in patients with Paget’s disease. Creatine phosphokinase is often elevated in patients with polymyositis. A detailed blood test and blood biochemistry allows diagnosing hepatitis.

Fibromyalgia may present on its own or in association with systemic rheumatic diseases. In systemic rheumatological diseases (SLE, rheumatoid arthritis, polymyositis), inflammation and damage to various tissues and organs occur. For the diagnosis of these diseases, such analyzes as ESR plasma protein levels, antinuclear factor, C reactive protein, sialic acid are important. With fibromyalgia, these tests are within the normal range.

Treatment

Because the symptoms of fibromyalgia vary greatly from patient to patient, treatment programs must be personalized for each patient. Fibromyalgia treatment programs are most effective when combined with pharmacological and non-pharmacological treatments.

Stress reduction

It is practically impossible to measure stress levels in different patients. For some people, spilled milk on the table is almost a tragedy. And for others, even if the tank drives into the room, there will be no concern. A good effect for reducing stress is given by biofeedback and relaxation techniques. Sometimes, changes in environmental factors (such as noise, temperature, weather changes) are enough to increase the symptoms of fibromyalgia. And the impact on these factors can have a positive impact. Optimal amount of sleep is very helpful.

Exercise therapy

Low-intensity physical activity such as swimming, cycling, walking Especially beneficial in the morning. The mechanism by which exercise influences fibromyalgia is not known. One factor may be improved sleep (prolongation of REM sleep).

Diet

There is no specific diet for the treatment of fibromyalgia. It is recommended to avoid drinking alcohol and coffee in the evening in order to improve sleep. In the presence of irritable bowel syndrome, it is necessary to avoid products that provoke violations of the gastrointestinal tract.

Drug treatment

Traditionally, tricyclic antidepressants, commonly used to treat depression, have been considered most effective. In the treatment of fibromyalgia, tricyclic antidepressants are used at dosages several times lower than in the treatment of depression. Tricyclic antidepressants relieve fatigue to some extent, reduce muscle pain, and improve sleep. Science believes this is due to a change in the levels of a neurotransmitter called serotonin. A tricyclic antidepressant is, for example, amitriptyline or doxepin. Practice has shown that the combination of drugs such as fluoxetine (Prozac) with a reduced dose of amitriptyline increases the reduction of symptoms, improves sleep and well-being. But these drugs unfortunately have side effects.